Table 3.

Results indicating that there was a high consensus that ambulation in patients should be preserved for as long as possible

Theme	Statement	Overall Agreement	Consensus
Loss of ambulation	Ataluren (in addition to standard of care) significantly delays the loss of ambulation in patients with nmDMD	85.0%	High
	Ataluren (in addition to standard of care) is expected to result in the same treatment effect in each surviving muscle fibre irrespective of the nmDMD patients’ ambulatory status	65.0%	None
	If a nmDMD patient receiving ataluren loses ambulation, they should continue treatment with ataluren	95.0%	Very high
	There is life beyond loss of ambulation. There are still lots of important functions of the muscles such as being able to use the hands and arms, fine motor skills and respiratory muscles – all these functions should be maintained for as long as possible	100.0%	Very high
	Delaying the loss of ambulation in patients with nmDMD may reduce the development of scoliosis	90.0%	High
	Delaying the loss of ambulation in patients with nmDMD delays the decline of respiratory function	100.0%	Very high
	Delaying the loss of ambulation in patients with nmDMD is related to the decline of upper limb function	75.0%	High

The threshold for consensus defined as > 66%, with consensus being defined as high at > 66% and very high at > 90% of respondents selecting agree or strongly agree